What is Juvenescence?
Juvenescence Limited operates at the intersection of biotechnology and longevity science, focusing on the development of therapies designed to modify the aging process and extend human healthspan. Founded by a consortium of seasoned drug developers and entrepreneurs, the company employs a hybrid business model that involves in-licensing academic compounds, forming strategic joint ventures, and incubating new therapeutic entities. By leveraging recent breakthroughs in the understanding of cellular senescence and metabolic health, Juvenescence aims to commercialize interventions that could potentially halt or reverse age-related decline, positioning itself as a leader in the emerging longevity therapeutics market.
How much funding has Juvenescence raised?
Juvenescence has raised a total of $256.9M across 4 funding rounds:
Angel/Seed
$50M
Series A
$50M
Series B
$100M
Series C
$56.9M
Angel/Seed (2018): $50M, investors not publicly disclosed
Series A (2018): $50M, investors not publicly disclosed
Series B (2019): $100M supported by IPGL and Grok Ventures
Series C (2020): $56.9M, investors not publicly disclosed
Key Investors in Juvenescence
IPGL
IPGL Limited is a private holding company that partners with experienced management teams to build fast-growing businesses and develop industry leaders over the long term.
Grok Ventures
Grok Ventures LLC is a venture capital and private equity firm focused on identifying and scaling high-potential companies across diverse sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Juvenescence?
With the infusion of capital from its latest funding round, Juvenescence is well-positioned to accelerate its clinical trial programs and expand its portfolio of longevity-focused assets. The company's strategic roadmap emphasizes the scaling of its internal R&D capabilities while maintaining a disciplined approach to partnership-driven growth. As the global demand for age-related medical solutions intensifies, Juvenescence is expected to focus on regulatory milestones and the commercialization of its lead candidates. The firm remains a critical entity for investors tracking the intersection of high-growth biotech and the burgeoning longevity economy, with a clear mandate to translate complex biological research into viable, market-ready therapeutic products.
See full Juvenescence company page
